The Metoclopramide for Avoiding Pneumonia after Stroke trial

MAPS-2

Purpose:
Is to assess whether metoclopramide (antiemetic) reduces aspiration pneumonia and mortality in patients with moderate to severe strokes swallowing difficulties

Who will have been recruited?

- Adults with acute stroke
- Within 24 hours of symptom onset
- NIHSS 10 or more **Or** NIHSS between 6-9 with a failed swallow screen
- Consent by patient (or relative) to take part

Why is this ward involved?

- Patients eligible to take part in MAPS-2 may be on this ward.
- Their trial treatment and clinical observations need to continue up to day 14 or day of discharge if earlier.

Treatment allocation and blinding:

- Participants will have been randomly allocated to receive metoclopramide or normal saline for a maximum of 42 doses/14 days.
- They have an equal chance of receiving either treatment, it is important that participant and their families do not know which intervention they have been allocated.
- **Metoclopramide (IV preparation) or normal saline will be administered by NG or IV, 3 times per day as per drug chart. No other preparation is approved.**
- Scan the QR code to watch video guidance on how to give Maps-2 trial drug:

- **If the participant becomes unwell in any way, please inform the research team as soon as possible.**
- Please make the research team aware of any issues with the administration or unblinding of the trial treatment.

PI is :

Research nurses:

Contact tel no. / email